About
Neurogenic is a clinical-stage diagnostics company developing sensitive immunoassays to assist in the diagnosis of mental disorders. The company has established long-term collaborations with the Weizmann Institute of Science, Rehovot, the Department of Psychiatry, Faculty of Medicine, Tel Aviv University, Tel Aviv, the Beer Yaakov-Ness-Ziona Mental Health Center, Ness Ziona, the Geha Mental Health Center, Petach Tikva, and the Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, Beilinson Campus, Rabin Medical Center, Petah Tikva, Israel to develop a straightforward, sensitive ELISA-based immunoassay to detect the autoimmune Platelet-Associated Antibodies (PAA) in the sera of adolescent and pediatric patients suffering from early-onset symptoms of schizophrenia. Neurogenic is now in the final stages of assay optimization. The company is continuing clinical field testing and validation of the assay.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Neurogenic's primary focus as a company?
- Neurogenic is a clinical-stage diagnostics company that develops sensitive immunoassays to aid in the diagnosis of mental disorders.
- When was Neurogenic founded?
- Neurogenic was founded in February 1995.
- What is the current development stage of Neurogenic's diagnostic assay?
- Neurogenic is in the final stages of assay optimization for its ELISA-based immunoassay and is continuing clinical field testing and validation.
- Which institutions does Neurogenic collaborate with for its research and development?
- Neurogenic has established long-term collaborations with the Weizmann Institute of Science, Tel Aviv University's Department of Psychiatry, Beer Yaakov-Ness-Ziona Mental Health Center, Geha Mental Health Center, and the Laboratory of Biological Psychiatry at Felsenstein Medical Research Center.
- What is the specific application of Neurogenic's immunoassay?
- Neurogenic's immunoassay is designed to detect autoimmune Platelet-Associated Antibodies (PAA) in the sera of adolescent and pediatric patients with early-onset schizophrenia symptoms.
- What is the name of Neurogenic's diagnostic product?
- Neurogenic's diagnostic product is called the Schizophrenia ELISA Diagnostic Assistant (SEDA) Assay.
- What was a significant partnership announced by Neurogenic in March 2019?
- In March 2019, Neurogenic announced a deal with SYnAbs for schizophrenia detection.
- How many employees does Neurogenic currently have?
- Neurogenic currently has 1-10 employees.